CSRXP ENCOURAGES HOUSE JUDICIARY COMMITTEE TO CRACK DOWN ON BIG PHARMA’S PATENT ABUSE

Committee Mark Up Targets Brand Name Drug Companies’ Anti-Competitive Tactics That Undermine More Affordable Alternatives

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement today in advance of a U.S. House of Representatives Committee on the Judiciary mark up of two bills that would crack down on the pharmaceutical industry’s patent abuse and promote competition in the pharmaceutical market.

“CSRxP commends Chairman Nadler and members of the Judiciary Committee for taking up important solutions that will hold Big Pharma accountable and help stop brand name drug companies from gaming the system to undermine competition,” said CSRxP executive director Lauren Aronson. “CSRxP encourages committee members to advance these bills that will crack down on Big Pharma’s anti-competitive tactics like product hopping and add to the momentum in Washington to lower prescription drug prices.”

The following bills being heard before the Committee on the Judiciary are supported by CSRxP:

• The Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act targets Big Pharma abuse of the Food and Drug Administration’s (FDA’s) citizen petition process to delay generic drug applications.
• The Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 targets an abusive Big Pharma tactic called “product hopping” used to game the patent system and unfairly extend product monopolies.

Learn more on market-based solutions to hold Big Pharma accountable and lower prescription drug prices HERE.